{
  "emaEpar": [
    {
      "activeSubstance": "Eribulin",
      "conditionIndication": "Halaven monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease (see section 5.1). Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.Halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see section 5.1).",
      "inn": "eribulin",
      "marketingAuthorisationDate": "2011-03-17 01:00:00",
      "marketingAuthorisationHolder": "Eisai GmbH",
      "medicineName": "Halaven",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/halaven"
    }
  ],
  "fdaDrugLabel": [],
  "id": "Eribulin",
  "nciThesaurus": {
    "casRegistry": "253128-41-5",
    "chebiId": "CHEBI:63587",
    "chemicalFormula": "C40H59NO11",
    "definition": "An analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.",
    "fdaUniiCode": "LR24G6354G",
    "identifier": "C96748",
    "preferredName": "Eribulin",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C67422"
    ],
    "synonyms": [
      "2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one",
      "ER-086526",
      "ERIBULIN",
      "Eribulin"
    ]
  }
}